IQ-AI Limited

Equities

IQAI

JE00BD4H0R42

Healthcare Facilities & Services

Market Closed - London S.E. Other stock markets 11:35:11 2024-05-10 am EDT			5-day change	1st Jan Change
1.65 ^GBX	0.00%		+3.12%	-64.89%

May. 10	IQ-AI subsidiary gets rare paediatric disease designation FDA	AN
May. 10	IQ-AI's Imaging Biometrics Obtains Rare Pediatric Disease Designation for Lead Drug Candidate	MT

Iq-Ai Limited Reports Earnings Results for the Half Year Ended June 30, 2021

August 27, 2021 at 04:58 am EDT

IQ-AI Limited announced earnings results for the half year ended June 30, 2021. For the half year, the company announced sales was GBP 238,488 compared to GBP 116,842 a year ago. Operating loss was GBP 201,824 compared to GBP 346,944 a year ago. Net loss was GBP 207,135 compared to GBP 367,205 a year ago. Basic loss per share was GBP 0.0012 compared to GBP 0.0025 a year ago.

Latest news about IQ-AI Limited

IQ-AI subsidiary gets rare paediatric disease designation FDA	May. 10	AN
IQ-AI's Imaging Biometrics Obtains Rare Pediatric Disease Designation for Lead Drug Candidate	May. 10	MT
EARNINGS AND TRADING: Trident Royalties swings to profit	May. 02	AN
IQ-AI Limited Provides Revenue Guidance for the Financial Year 2024	Apr. 29	CI
IQ-AI Limited Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 29	CI
IQ-AI's Broker Exercises Option to Buy Shares in Placing	Feb. 26	MT
IQ-AI Plans Share Placing to Advance Oral Anti-tumor Agent Development	Feb. 22	MT
IQ-AI shares sink on discounted placing fundraise	Feb. 22	AN
IQ-AI Unit to Revise, Resubmit Pediatric Rare Disease Designation Application After US FDA Feedback	Feb. 09	MT
IQ-AI subsidiary asked by FDA to resubmit and modify application	Feb. 09	AN
IQ-AI Unit Secures Grant for Brain Tumor Pill Access Program	Feb. 02	MT
IQ-AI celebrates USD100,000 grant for subsidiary	Feb. 02	AN
IQ-AI falls after subsidiary notes launch of treatment access scheme	Jan. 10	AN
IQ-AI's Imaging Biometrics Plans Expanded Access Program for Brain Tumor Treatment	Jan. 10	MT
IQ-AI Subsidiary’s Glioblastoma Therapy Obtains Fast-Track Designation From US FDA	Dec. 19	MT
IQ-AI firm gets US FDA fast-track status for oral gallium maltolate	Dec. 19	AN
IQ-AI's Imaging Biometrics Discloses Positive Results in Early-stage Study of Potential Brain Cancer Treatment	Dec. 05	MT
IQ-AI stock rises on positive interim results from glioblastoma trial	Dec. 05	AN
IQ-AI Unit Seeks Pediatric Rare Disease Designation for Brain Tumor Treatment	Nov. 08	MT
IQ-AI says Imaging Biometrics submits paediatric rare disease request	Nov. 08	AN
IQ-AI Applies for FDA Pediatric Rare Disease Designation	Nov. 08	CI
IQ-AI subsidiary "central" to "landmark" brain cancer study	23-10-18	AN
IQ-AI subsidiary wins orphan drug designation from US FDA	23-10-09	AN
IQ-AI's Atypical Teratoid Rhabdoid Tumor Treatment Gains US FDA Orphan Drug Designation	23-10-09	MT
IQ-AI Halts Trading on OTCQB Venture Market in US; London Shares Up 13%	23-09-19	MT

Chart IQ-AI Limited

Duration

Period

More charts

Company Profile

IQ-AI Limited is a Jersey-based company, which is engaged in the provision of clinical treatments to patients in the field of medical imaging diagnostics, based on technology. The Company operates through two segments: holding company expenses and medical software. Its subsidiaries include Imaging Biometrics, LLC and Stone Checker Software Limited. Imaging Biometrics, LLC is a healthcare imaging software company. In addition to providing regulatory consulting services, Imaging Biometrics, LLC supplies medical technology solutions and has a neuroimaging product portfolio. Stone Checker Software Limited is a supplier of technology solutions in the field of kidney stone analysis and kidney stone prevention.

Sector

Healthcare Facilities & Services

Calendar

2024-05-29 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Sector Medical & Diagnostic Laboratories

	1st Jan change	Capi.
IQ-AI LIMITED	-64.89%	4.58M
SONIC HEALTHCARE LIMITED	-16.38%	8.49B
RADNET, INC.	+58.90%	4.08B
GUANGZHOU KINGMED DIAGNOSTICS GROUP CO., LTD.	-39.78%	2.42B
SYNLAB AG	-10.33%	2.42B
DR. LAL PATHLABS LIMITED	-8.91%	2.33B
NEOGENOMICS, INC.	-2.53%	2.01B
FLEURY S.A.	-19.90%	1.53B
DIAN DIAGNOSTICS GROUP CO.,LTD.	-38.30%	1.26B
METROPOLIS HEALTHCARE LIMITED	+2.19%	1.07B

Medical & Diagnostic Laboratories